ERCC1 and topoisomerase I expression in small cell lung cancer: Prognostic and predictive implications

International Journal of Oncology

Volumn 40, Issue 6, 2012, Pages 2104-2110

  Sereno Moyano, Maria ^a   Cejas, Paloma ^b   Moreno, Víctor ^b   Belda Iniesta, Cristóbal ^b   López, Rocio ^b   Nistal, Manuel ^b   Feliu, Jaime ^b   Carpeño, Javier De Castro ^b  

^a HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Cisplatin response; Excision repair cross complementation group 1; Prognosis; Small cell lung cancer; Topoisomerase I

Indexed keywords

CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE; DOXORUBICIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MESSENGER RNA; NAVELBINE; PACLITAXEL; PLATINUM; TOPOTECAN; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE I; DNA-BINDING PROTEINS; DOXORUBICIN; ENDONUCLEASES; ETOPOSIDE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; TRANSCRIPTION, GENETIC; VINCRISTINE;

EID: 84861791689     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1378     Document Type: Article

References (40)

1. Jackman DM and Johnson BE: Small cell lung cancer. Lancet 366: 1385-1396, 2005.
2. Sandler AB: Chemotherapy for small cell lung cancer. Semin Oncol 30: 9-25, 2003.
3. Lawley PD and Phillips DH: DNA adducts from chemotherapeutic agents. Mutat Res 355: 13-40, 2004.
4. Phyllip P and Mallen H: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311: 899-909, 2001.
5. Mu D, Hsu DS and Sancar A: Reaction mechanism of human DNA repair excision nuclease. J Biol Chem 271: 8285-8294, 1996. (Pubitemid 26108661)
6. Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, et al: The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand crosslink-induced double-strand breaks. Mol Cell Biol 24: 5776-5778, 2004.
7. Sancar A: Mechanisms of DNA excision repair. Science 266: 1954-1956, 1994.
8. Zamble DB, Mu D, Reardon JT, et al: Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 35: 10004-10013, 1997.
9. Li Q, Yu JJ, Mu C, Yunmbam MK, et al: Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 20: 645-652, 2002.
10. Metzger R, Leichman CG, Danenberg KD, et al: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309-316, 1998. (Pubitemid 28041614)
11. Shirota Y, Stoehlmacher J, Brabender J, et al: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19: 4298-4304, 2001. (Pubitemid 33096777)
12. Joshi MB, Shirota Y, Danenberg KD, et al: High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 11: 2215-2221, 2005.
13. Lord RV, Brabender J, Gandara D, et al: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8: 2286-2291, 2002. (Pubitemid 34753602)
14. Simon GR, Sharma S, Cantor A, et al: ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127: 978-983, 2007.
15. Lee H, Han H, Kim JH, et al: Expression of excision repair cross complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer 59: 95-104, 2004.
16. Ceppi P, Longo M, Volante M, et al: Excision repair cross complementing- 1 and topoisomerase II gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study. J Thorac Oncol 3: 583-589, 2008. (Pubitemid 351787300)
17. Chhatriwala H, Jafri N and Salgia R: A review of topoisomerase inhibition in lung cancer. Cancer Biol Ther 5: 1600-1607, 2006.
18. Jett JR, Hatfield A, Bauman M, et al: Phase II trial of topotecan and paclitaxel (TP) with G-CSF support alternating with etoposide and cisplatin (EC) in previously untreated extensive stage small cell lung cancer (ED-SCLC): a North Central Cancer Treatment Group study. Lung Cancer 29: 52-57, 2007.
19. Hainsworth JD, Gray JR, Burris HA, et al: Paclitaxel, carboplatin and topotecan as initial therapy for small cell lung cancer. Lung Cancer 29: 40, 2000.
20. Gillenwater HH, McCune JS, Donahue AE, et al: Phase I trial of topotecan (T), carboplatin, and etoposide (E) for extensive stage small cell lung cancer. Lung Cancer 29: p67, abs. 127, 2000.
21. Ventriglia M, Cabrera L, Maidana M, et al: A phase II trial of topotecan (Hycamtin) with ifosfamide (Duvaxan) plus mesna (Mesnex) as first line treatment inpatients (pts) with small cell lung cancer (SCLC. A preliminary report. Lung Cancer 29: p67, abs. 218, 2000.
22. Zelen M: Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3: 31-34, 1973.
23. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1973.
24. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991, 2006. (Pubitemid 44343542)
25. Bellmunt J, Paz-Ares L and Cuello M: Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 18: 522-528, 2007. (Pubitemid 46359633)
26. Quintela-Fandino M, Hitt R, Medina PP, et al: DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 24: 4333-4339, 2006. (Pubitemid 46630792)
27. Handra-Luca A, Hernandez J, Mountzios G, et al: Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 13: 38-55, 2007.
28. Reed E: ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 11: 6100-6102, 2005.
29. Recka M, Grotha M, Buchholzb E, et al: Topotecan and etoposide as first- line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen. Lung Cancer 48: 409-413, 2005.
30. Hanna N, Bunn PA Jr, Langer C, et al: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24: 2038-2043, 2006. (Pubitemid 46622112)
31. Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346: 85-91, 2004.
32. Sorensen M, Lassen U, Jensen PB, et al: Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease. J Thorac Oncol 3: 902-906, 2008.
33. Ohashi N, Fujiwara Y, Yamaoka N, et al: No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer. Jpn J Cancer Res 87: 1280-1287, 1996. (Pubitemid 27042372)
34. Tsavaris N, Lazaris A, Kosmas C, et al: Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy. Cancer Chemother Pharmacol 64: 391-398, 2009.
35. Paradiso A, Xu J, Mangia A, et al: A topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. Int J Cancer 20: 252-258, 2004. (Pubitemid 38924703)
36. Rothenberg ML: Topoisomerase I inhibitors: review and uptodate. Ann Oncol 8: 837-855, 1997.
37. Mukai M, Sato S, Ninomiya H, et al: Sensitivity to CPT-11 and platinum derivatives of stage I/II node-negative breast, lung, and gastric cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep 18: 33-39, 1997.
38. Madden KR and Champoux JJ: Over expression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to campthoteicinas. Cancer Res 52: 525-532, 1992.
39. McLeod HL and Keith WN: Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br J Cancer 74: 508-512, 1996. (Pubitemid 26279043)
40. Kohara H, Massahiro T and Kiura K: Synergistic effects of topoisomerase I inhibitor, 7-etyl-10-hydroxycampthotecines and irradiation in a cisplatin-resistant human small cell lung cancer cell line. Clin Cancer Res 8: 287-292, 2002. (Pubitemid 34101490)